Umbilical cord blood for cardiovascular cell therapy: from promise to fact

Authors

  • Santiago Roura,

    1. ICREC Research Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Barcelona, Spain.
    Search for more papers by this author
  • Josep-Maria Pujal,

    1. ICREC Research Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Barcelona, Spain.
    Search for more papers by this author
  • Antoni Bayes-Genis

    1. ICREC Research Group, Health Sciences Research Institute Germans Trias i Pujol (IGTP), Barcelona, Spain.
    2. Cardiology Service, University Hospital Germans Trias i Pujol, Barcelona, Spain.
    3. Department of Medicine, Autonomous University Barcelona, Spain.
    4. Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
    Search for more papers by this author

Address for correspondence: Antoni Bayes-Genis, M.D., Ph.D., FESC, ICREC (Heart Failure and Cardiac Regeneration) Research Group, Cardiology Service, University Hospital Germans Trias i Pujol, Crta. Canyet, s/n, 08916 Badalona, Barcelona, Spain. abayes.germanstrias@gencat.cat

Abstract

Endothelial recovery and cell replacement are therapeutic challenges for cardiovascular medicine. Initially employed in the treatment of blood malignancies due to its high concentration of hematological precursors, umbilical cord blood (UCB) is now a non-controversial and accepted source of both hematopoietic and non-hematopoietic progenitors for a variety of emerging cell therapies in clinical trials. Here, we review the current therapeutic potential of UCB, focusing in recent evidence demonstrating the ability of UCB-derived mesenchymal stem cells to differentiate into the endothelial lineage and to develop new vasculature in vivo.

Ancillary